Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-26 4:15 pm Purchase |
2024-11-22 | 13D | Verrica Pharmaceuticals Inc. VRCA |
Manning Paul B | 52,504,049 49.900% |
37,114,568 (+241.17%) |
Filing History |
| 2024-11-12 5:35 pm Purchase |
2024-09-30 | 13G | Liquidia Corporation LQDA |
Manning Paul B | 6,679,132 7.900% |
350,411 (+5.54%) |
Filing History |
| 2024-02-14 4:18 pm Purchase |
2023-12-31 | 13G | Liquidia Corporation LQDA |
Manning Paul B | 6,328,721 9.200% |
304,608 (+5.06%) |
Filing History |
| 2023-08-21 4:01 pm Purchase |
2023-08-16 | 13D | Taysha Gene Therapies, Inc. TSHA |
Manning Paul B | 23,476,333 12.600% |
16,486,472 (+235.86%) |
Filing History |
| 2023-02-14 6:28 pm Unchanged |
2022-10-22 | 13G | Pasithea Therapeutics Corp. KTTA |
Manning Paul B | 170,435 11.300% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:24 pm Sale |
2022-12-31 | 13G | Acumen Pharmaceuticals, Inc. ABOS |
Manning Paul B | 3,205,128 7.800% |
-805,550 (-20.09%) |
Filing History |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | Liquidia Corporation LQDA |
Manning Paul B | 6,024,113 9.300% |
848,941 (+16.40%) |
Filing History |
| 2022-11-02 4:02 pm Purchase |
2022-10-31 | 13D | Taysha Gene Therapies, Inc. TSHA |
Manning Paul B | 6,989,861 11.200% |
1,694,554 (+32.00%) |
Filing History |
| 2022-07-15 4:15 pm Purchase |
2022-07-05 | 13D | Verrica Pharmaceuticals Inc. VRCA |
Manning Paul B | 15,389,481 37.400% |
4,761,904 (+44.81%) |
Filing History |
| 2022-06-29 4:30 pm Purchase |
2022-06-22 | 13G | Pasithea Therapeutics Corp. KTTA |
Manning Paul B | 170,435 9.800% |
170,435 (New Position) |
Filing History |
| 2022-02-14 7:27 pm Purchase |
2021-12-31 | 13G | Acumen Pharmaceuticals, Inc. ABOS |
Manning Paul B | 4,010,678 9.900% |
4,010,678 (New Position) |
Filing History |
| 2022-02-14 4:38 pm Purchase |
2021-07-29 | 13D | Candel Therapeutics, Inc. CADL |
Manning Paul B | 4,073,316 13.600% |
4,073,316 (New Position) |
Filing History |
| 2022-02-14 4:37 pm Purchase |
2021-12-31 | 13G | Verrica Pharmaceuticals Inc. VRCA |
Manning Paul B | 10,627,577 38.600% |
789,830 (+8.03%) |
Filing History |
| 2022-02-14 4:31 pm Purchase |
2021-12-31 | 13G | Liquidia Corporation LQDA |
Manning Paul B | 5,175,172 10.000% |
233,131 (+4.72%) |
Filing History |
| 2021-02-16 4:04 pm Purchase |
2020-12-31 | 13G | Verrica Pharmaceuticals Inc. VRCA |
Manning Paul B | 9,837,747 38.000% |
194,500 (+2.02%) |
Filing History |
| 2021-02-16 4:04 pm Purchase |
2020-12-31 | 13G | Liquidia Corporation LQDA |
Manning Paul B | 4,942,041 11.400% |
4,942,041 (New Position) |
Filing History |
| 2020-10-05 5:26 pm Purchase |
2020-09-23 | 13D | Taysha Gene Therapies, Inc. TSHA |
Manning Paul B | 5,295,307 14.300% |
5,295,307 (New Position) |
Filing History |